217 related articles for article (PubMed ID: 37532715)
1. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.
Bhasin SS; Thomas BE; Summers RJ; Sarkar D; Mumme H; Pilcher W; Emam M; Raikar SS; Park SI; Castellino SM; Graham DK; Bhasin MK; DeRyckere D
Sci Rep; 2023 Aug; 13(1):12556. PubMed ID: 37532715
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS; Porter CC; Castellino SM; Graham DK; Bhasin M
Genome Med; 2023 Oct; 15(1):83. PubMed ID: 37845689
[TBL] [Abstract][Full Text] [Related]
3. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
Mumme H; Thomas BE; Bhasin SS; Krishnan U; Dwivedi B; Perumalla P; Sarkar D; Ulukaya GB; Sabnis HS; Park SI; DeRyckere D; Raikar SS; Pauly M; Summers RJ; Castellino SM; Wechsler DS; Porter CC; Graham DK; Bhasin M
Nat Commun; 2023 Oct; 14(1):6209. PubMed ID: 37798266
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.
Mikami T; Kato I; Wing JB; Ueno H; Tasaka K; Tanaka K; Kubota H; Saida S; Umeda K; Hiramatsu H; Isobe T; Hiwatari M; Okada A; Chiba K; Shiraishi Y; Tanaka H; Miyano S; Arakawa Y; Oshima K; Koh K; Adachi S; Iwaisako K; Ogawa S; Sakaguchi S; Takita J
Cancer Sci; 2022 Jan; 113(1):41-52. PubMed ID: 34716967
[TBL] [Abstract][Full Text] [Related]
7. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Willoughby M
Leuk Lymphoma; 2001 Jan; 40(3-4):279-85. PubMed ID: 11426549
[TBL] [Abstract][Full Text] [Related]
9. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
10. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
11. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
12. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
13. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
14. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.
Zuurbier L; Gutierrez A; Mullighan CG; Canté-Barrett K; Gevaert AO; de Rooi J; Li Y; Smits WK; Buijs-Gladdines JG; Sonneveld E; Look AT; Horstmann M; Pieters R; Meijerink JP
Haematologica; 2014 Jan; 99(1):94-102. PubMed ID: 23975177
[TBL] [Abstract][Full Text] [Related]
15. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
16. Microenvironmental cues for T-cell acute lymphoblastic leukemia development.
Passaro D; Quang CT; Ghysdael J
Immunol Rev; 2016 May; 271(1):156-72. PubMed ID: 27088913
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
[TBL] [Abstract][Full Text] [Related]
20. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
